Skip to main content
editorial
. 2019 Jan 1;5(1):41–43.

Table 2.

FDA recommendations for analysis of clinical trials evaluating treatments for weight loss

Primary efficacy endpoint Mean: the difference in mean percentage loss of baseline body weight in the active-product versus placebo-treated group
Categorical: the proportion of subjects who lose at least 5% of baseline body weight in the active-product versus placebo-treated group
Secondary efficacy endpoints Should include, but are not limited to, changes in the following metabolic parameters:
  • Blood pressure and pulse

  • Lipoprotein lipids

  • Fasting glucose and insulin

  • HbA1c (in type 2 diabetics)

  • Waist circumference